Navigation Links
Antibodies in Medical Technology
... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody ...
... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody ...
... on two fully human anti-PS (phosphatidylserine) antibodies were presented by its collaboration partner ... that the anti-tumor effects observed with anti-PS antibodies reflect their immunomodulatory mechanism of ... in a preclinical model of prostate cancer. Both antibodies were isolated using Affitech's unique MBAS ...
... Anti-Tumor Potential of Fully Human Anti-PS antibodies and Expand the Company's PS-Targeting Platform- ... biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus ... its fully human phosphatidylserine (PS)-targeting antibodies demonstrated encouraging signs of efficacy in a ...
... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... data indicate that after Micromet developed BiTE antibodies from the EGFR-specific monoclonal antibodies Erbitux(R) (cetuximab) and Vectibix(R) ...
... and safety data from multiple programs, including antibodies to novel and potentially important cancer targets ... Development of anti-Glypican 3 therapeutic antibodies (Abstract #1233) Glypican-3 is a protein that ... cancer. A panel of fully human anti-glypican-3 antibodies was generated from which a lead candidate, ...
... Studies Highlight the Ability of PS-Targeting antibodies to Reverse the Immune Suppressing Effects of ... - Studies Confirm Peregrine's PS-Targeting antibodies Stimulate Dendritic Cell Maturation, Inflammatory ... biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus ...
... the monovalent binding to normal cells of other antibodies confirming that only nimotuzumab will avoid ... result of properties intrinsic to the individual antibodies or to the class. The results show that Erbitux(R) ... that results in its benign safety profile. Both antibodies bind definitively when binding bivalently. The ...
... to 16, 2009: Update on several preclinical BiTE antibodies at the American Association for Cancer Research ... and 10, 2009, in New York, NY. About BiTE antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ...
... tract infection. No patient tested positive for antibodies to ofatumumab.(1) "There is a great ... from the binding sites targeted by other CD20 antibodies currently available or in development.(5) The ... The Biological Activity of Human CD20 Monoclonal antibodies Is Linked to Unique Epitopes on CD20. J Immunol ...
... status. Recent studies suggest that anti-EGFR antibodies cetuximab (Erbitux(R); ImClone, BMS, Merck KGaA) ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the ...
... The research links naturally occurring antibodies against phosphorylcholine (PC) to ... and the prospects for development of therapeutic antibodies to treat cardiovascular inflammation. ... with Athera and the prospects for development of antibodies to phosphorylcholine include the risks that: ...
... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the ... of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new ...
... serum levels needed by conventional monoclonal antibodies for achieving a tumor regression in this disease. ... Officer Carsten Reinhardt, M.D. Typically antibodies cannot engage T cells because T cells lack ... to escape recognition by T cells. The use of antibodies that are specifically designed to engage T cells ...
... trial participants. MabVax plans to rescue antibodies from these patient samples to create a pipeline ... on the surface of the cancer cells. By rescuing antibodies from a selection of patients who generate a ... Vaccines, or passively administered antibodies developed from these vaccines, produced evidence ...
... by Genentech of the anti-CD4 monoclonal antibodies in autoimmune or other indications. Tolerx may ... on worldwide net sales of the anti-CD4 monoclonal antibodies that Genentech successfully develops. In lieu of ... and promote and enhance immune responses. These antibodies are being assessed for potential benefit in the ...
... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the ... BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's own ...
... group (GMALL). About BiTE Antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ... new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological ... tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios ...
... Lugano, 2008. About BiTE Antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ... new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological ... tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios ...
... and CLL. About BiTE Antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ... new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological ... tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios ...
... the treatment of haematological cancers. "BiTE antibodies enable the patients' own T cells to very ... to metastases." About BiTE Antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ... new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological ...
... Secondary endpoint results suggest that levels of antibodies against beta-amyloid were observed to have ... Relkin also reported observations that levels of antibodies against beta-amyloid increased in the ... IGIV products can contain blood group antibodies that may cause a positive direct antiglobulin ...
... on the surface of targeted cells, these anti-PS antibodies could create a unique tumor microenvironment, by ... and CEO of Peregrine. "We know that these antibodies can combat cancer by targeting the PS located on ... PS and its anti-inflammatory signals, our anti-PS antibodies unleash powerful pro-inflammatory effects ...
... Anti-PS Vascular Targeting antibodies - SAN DIEGO and TUSTIN, Calif., April 15 ... combining its anti-phosphatidylserine (anti-PS) antibodies and cytokines such as IL-2 to generate robust ... provides further evidence that our anti-PS antibodies have the potential to reverse the ...
... ), a biopharmaceutical company developing novel antibodies for the treatment of cancer, inflammation and ... (AML) and melanoma (1). BiTE antibodies are designed to direct the body's cytotoxic, or ... Generation of human anti-CD33 and anti-MCSP BiTE antibodies used a novel human BiTE antibody platform that is ...
... CA, data showing that commercial anti-cancer antibodies trastuzumab (Herceptin(R); Genentech, ... successfully converted into a BiTE antibody. BiTE antibodies are designed to direct the body's cytotoxic, or ... of cancer and other diseases. All four BiTE antibodies were constructed using Micromet's ...
... have shown the potential efficacy of our anti-PS antibodies in combination with both existing and ... potential versatility of our anti-PS antibodies in combination cancer therapy. We look forward to ... clinical studies of bavituximab and other anti-PS antibodies in a broad range of anti-cancer regimens." Dr. ...
... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody ...
... on two fully human anti-PS (phosphatidylserine) antibodies were presented by its collaboration partner ... that the anti-tumor effects observed with anti-PS antibodies reflect their immunomodulatory mechanism of ... in a preclinical model of prostate cancer. Both antibodies were isolated using Affitech's unique MBAS ...
Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... data presented at AACR demonstrated that BiTE antibodies developed from the EGFR-specific monoclonal antibodies Erbitux(R) (cetuximab) and Vectibix(R) ...... Anti-Tumor Potential of Fully Human Anti-PS antibodies and Expand the Company's PS-Targeting Platform- ... biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus ... its fully human phosphatidylserine (PS)-targeting antibodies demonstrated encouraging signs of efficacy in a ...
... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... data indicate that after Micromet developed BiTE antibodies from the EGFR-specific monoclonal antibodies Erbitux(R) (cetuximab) and Vectibix(R) ...
... and safety data from multiple programs, including antibodies to novel and potentially important cancer targets ... Development of anti-Glypican 3 therapeutic antibodies (Abstract #1233) Glypican-3 is a protein that ... cancer. A panel of fully human anti-glypican-3 antibodies was generated from which a lead candidate, ...
... Studies Highlight the Ability of PS-Targeting antibodies to Reverse the Immune Suppressing Effects of ... - Studies Confirm Peregrine's PS-Targeting antibodies Stimulate Dendritic Cell Maturation, Inflammatory ... biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus ...
AACR Data Highlights InNexus Preclinical Antibody Candidate
... commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking ... commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the ... opening new markets and disease applications. DXL antibodies utilize unique, novel and patented methods and ...Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... antibody platform, representing a new class of antibodies that specifically activate T cells from the ...Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... antibody platform, representing a new class of antibodies that specifically activate T cells from the ...... the monovalent binding to normal cells of other antibodies confirming that only nimotuzumab will avoid ... result of properties intrinsic to the individual antibodies or to the class. The results show that Erbitux(R) ... that results in its benign safety profile. Both antibodies bind definitively when binding bivalently. The ...
... to 16, 2009: Update on several preclinical BiTE antibodies at the American Association for Cancer Research ... and 10, 2009, in New York, NY. About BiTE antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ...
... tract infection. No patient tested positive for antibodies to ofatumumab.(1) "There is a great ... from the binding sites targeted by other CD20 antibodies currently available or in development.(5) The ... The Biological Activity of Human CD20 Monoclonal antibodies Is Linked to Unique Epitopes on CD20. J Immunol ...
Micromet Expands Committed Equity Financing Facility to $75 Million
... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... The Company is developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... antibody platform to create a new class of antibodies that specifically activate T cells from the ...... status. Recent studies suggest that anti-EGFR antibodies cetuximab (Erbitux(R); ImClone, BMS, Merck KGaA) ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the ...
... The research links naturally occurring antibodies against phosphorylcholine (PC) to ... and the prospects for development of therapeutic antibodies to treat cardiovascular inflammation. ... with Athera and the prospects for development of antibodies to phosphorylcholine include the risks that: ...
InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
... commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking ... "The DXL(TM) technology platform builds better antibodies and soon you'll be able to see our strategy to ... mass" at the point of association. DXL(TM) antibodies have significantly extended dissociation rates, ...... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the ... of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new ...
Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
... breast and colon cancer. PAN-622 and other antibodies covered under U.S. Patent Number 7,413,737 were ... KD. Isolation and characterization of human antibodies targeting human aspartyl ... notice of the issuance of the patent covering antibodies against HAAH, and particularly PAN-622, our ...Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
... developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the ... BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, ...... serum levels needed by conventional monoclonal antibodies for achieving a tumor regression in this disease. ... Officer Carsten Reinhardt, M.D. Typically antibodies cannot engage T cells because T cells lack ... to escape recognition by T cells. The use of antibodies that are specifically designed to engage T cells ...
... trial participants. MabVax plans to rescue antibodies from these patient samples to create a pipeline ... on the surface of the cancer cells. By rescuing antibodies from a selection of patients who generate a ... Vaccines, or passively administered antibodies developed from these vaccines, produced evidence ...
... by Genentech of the anti-CD4 monoclonal antibodies in autoimmune or other indications. Tolerx may ... on worldwide net sales of the anti-CD4 monoclonal antibodies that Genentech successfully develops. In lieu of ... and promote and enhance immune responses. These antibodies are being assessed for potential benefit in the ...
Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the ... BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's own ...Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic
... vastly improves the development of monoclonal antibodies and Abeome is deploying its technology to provide a shotgun approach to develop an array of antibodies for an ovarian cancer therapeutic target. The ... to develop such a large library of monoclonal antibodies by use of their technology. They have pushed ...... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the ... BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's own ...
... group (GMALL). About BiTE Antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ... new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological ... tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios ...
... Lugano, 2008. About BiTE Antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ... new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological ... tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios ...
Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
... with Aegera Therapeutics. The HGS TRAIL receptor antibodies and small-molecule IAP inhibitors represent two ... cancers. HGS plans to develop its TRAIL receptor antibodies and IAP inhibitors in combination with ... HGS reacquired the rights to its TRAIL receptor antibodies from GSK in April 2008 in return for a reduction ...... and CLL. About BiTE Antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ... new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological ... tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios ...
CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
... generates sustained high levels of neutralizing antibodies against the two most common cervical ... to date. Experts believe that neutralizing antibodies -- so-called because they have the ability to ... addition, the study found that the level of total antibodies induced by the candidate vaccine was sustained ...... the treatment of haematological cancers. "BiTE antibodies enable the patients' own T cells to very ... to metastases." About BiTE Antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ... new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological ...
... Secondary endpoint results suggest that levels of antibodies against beta-amyloid were observed to have ... Relkin also reported observations that levels of antibodies against beta-amyloid increased in the ... IGIV products can contain blood group antibodies that may cause a positive direct antiglobulin ...
... on the surface of targeted cells, these anti-PS antibodies could create a unique tumor microenvironment, by ... and CEO of Peregrine. "We know that these antibodies can combat cancer by targeting the PS located on ... PS and its anti-inflammatory signals, our anti-PS antibodies unleash powerful pro-inflammatory effects ...
... Anti-PS Vascular Targeting antibodies - SAN DIEGO and TUSTIN, Calif., April 15 ... combining its anti-phosphatidylserine (anti-PS) antibodies and cytokines such as IL-2 to generate robust ... provides further evidence that our anti-PS antibodies have the potential to reverse the ...
Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
... administered BiTE(R) antibodies(1). BiTE antibodies are designed to direct the body's cytotoxic, or ... routes of administration for MT110 and other BiTE antibodies to further enhance the quality of life of ... No. 2403. About BiTE Antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ...... ), a biopharmaceutical company developing novel antibodies for the treatment of cancer, inflammation and ... (AML) and melanoma (1). BiTE antibodies are designed to direct the body's cytotoxic, or ... Generation of human anti-CD33 and anti-MCSP BiTE antibodies used a novel human BiTE antibody platform that is ...
... CA, data showing that commercial anti-cancer antibodies trastuzumab (Herceptin(R); Genentech, ... successfully converted into a BiTE antibody. BiTE antibodies are designed to direct the body's cytotoxic, or ... of cancer and other diseases. All four BiTE antibodies were constructed using Micromet's ...
... have shown the potential efficacy of our anti-PS antibodies in combination with both existing and ... potential versatility of our anti-PS antibodies in combination cancer therapy. We look forward to ... clinical studies of bavituximab and other anti-PS antibodies in a broad range of anti-cancer regimens." Dr. ...
Other ContentsOther Tags
(Date:5/22/2013)... health effects from disposal of millions of rechargeable ... recommend stronger government policies to encourage recovery, recycling ... the conclusion of a new paper in the ... , Oladele A. Ogunseitan and colleagues point out ... everything from smart phones to components in new ...
(Date:5/22/2013)... 2013 Early screening for prostate cancer could become ... for women, thanks to UC Irvine research published today ... . , After more than a decade of work, ... identify clinically usable markers for prostate cancer in urine, ... with greater accuracy and at dramatically lower cost. The ...
(Date:5/21/2013)... Using a "patient monitoring" device attached to a whale ... time how fishing lines changed a whale,s diving and ... whales, ability to eat and migrate, depletes their energy ... can result in a slow death. , The scientists ... a Dtag to a two-year-old female North Atlantic right ...
Breaking Biology News(10 mins):UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3(Date:5/22/2013)... (PRWEB) May 22, 2013 Jury deliberations are ... trial involving a da Vinci lawsuit, Bernstein Liebhard ... family of a man who allegedly died of da Vinci ... $8 million in damages from Intuitive Surgical, Inc. Among ... training program for the da Vinci Surgical System in its ...
(Date:5/22/2013)... Reporter , , WEDNESDAY, May 22 (HealthDay News) -- Anyone ... is something about feet that fungi seem to like. ... the fungal groups that live on your skin -- ... It,s no secret that the human body is ... fungi, both outside and inside. And it,s mainly a ...
(Date:5/22/2013)... 2013 DePuy Pinnacle lawsuit ... Hip Replacement System continue to move forward in the ... LLP reports. According to an Order dated May ... monitoring reports associated with a 2007 criminal investigation by ... practices. Plaintiffs maintained in their December 2012 ...
(Date:5/22/2013)... UT (PRWEB) May 22, 2013 Today, ... Alabama Health Insurance Exchange . Zane Benefits, which ... health benefits, is the leader in defined contribution ... According to Zane Benefits’ website, beginning in 2014 as ... coverage for individuals and small businesses will become available ...
(Date:5/22/2013)... may be reaping enormous income for patients whose ... contracted in their intensive care units. , In ... American Journal of Medical Quality , the ... an avoidable central line-associated bloodstream infection (CLABSI) costs ... a similar infection-free patient. Moreover, hospitals earn nearly ...
Breaking Medicine News(10 mins):Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 2Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 3Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 4Health News:Scientists Map the Fungi on Your Feet 2Health News:Scientists Map the Fungi on Your Feet 3Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 3Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4[0] Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications[0] Scientists Map the Fungi on Your Feet [0] DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation[0] Zane Benefits Publishes New Information on Alabama Health Insurance Exchange[0] Hospitals profit when patients develop bloodstream infections
ReactivatedWilliamsCelluloseManualMinusculeVolcanicMagicSyphilisCoatedColourCryoablationImmunizationOpeningFungal
Other Tags| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |